go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Shire Human Genetic Therapies

Shire Human Genetic Therapies
Hampshire International Business Park, Crockford Lane, Basingstoke, Hampshire, RG24 8EP, UK
Telephone: +44 1256 894 000
Medical Information e-mail: hgtmedcomm@shire.com
Summary of Product Characteristics last updated on medicines.ie: 28/03/2012
SPC Replagal 1mg/ml concentrate for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 28/03/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
Date of revision of text on the SPC:   01-Mar-2012
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

changes to layout, wording and updated information throught
Updated on 02/02/2010 and displayed until 28/03/2012
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   22-Dec-2009
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



In section 4.2 (Posology and method of administration), has been amended for paediatric patients.

Paediatric Patients

The experience in children is limited. No dosage regimen in children (0-6 years) can presently be recommended as safety and efficacy have not yet been sufficiently established.  Limited clinical data in children (7-18 years) do not permit to recommend an optimal dosage regimen presently (see sections 5.1 and 5.2). Because no unexpected safety issues were encountered in the 6 month study with Replagal administered at 0.2 mg/kg in this population, this dose regimen is suggested for children between 7– 18 years of age.

In section 4.4 (Special warnings and precautions for use).
Idiosyncratic infusion related reactions

13.7% of adult patients treated with Replagal in clinical trials have experienced idiosyncratic infusion related reactions.  Four of 17 (23.5%) paediatric patients >7 years of age enrolled in clinical trials experienced at least one infusion reaction over a period of 4.5 years of treatment (mean duration of approx. 4 years).  Three of 8 (37.5%) paediatric patients <7 years of age experienced at least one infusion related reaction over a mean observation time of 4.2 years… A review of cardiac events showed that infusion reactions may be associated with hemodynamic stress triggering cardiac events in patients with pre-existing cardiac manifestations of Fabry disease.

IgG antibodies to the protein

The remaining 76% remained antibody negative throughout. In paediatric patients >7 yrs of age, 1/16 male patients tested positive for IgG anti-agalsidase alfa antibodies during the study.  No increase in the incidence of adverse events was apparent for this patient.  In paediatric patients <7 yrs of age, 0/7 male patients tested positive for IgG anti-agalsidase alfa antibodies.

 


In section 4.8 (Undesirable effects), has been updated to specify paediatric sub-populations and includes cardiac events.

The most commonly reported undesirable effects were infusion associated reactions, which occurred in 13.7% of adult patients treated with Replagal in clinical trials.  Most undesirable effects were mild to moderate in severity.  Table 1 lists adverse drug reactions (ADRs) reported for the 177 patients treated with Replagal in clinical trials, including 21 patients with history of endstage renal disease, 24 paediatric patients (7 to 17 years of age)  and 17 female patients. 

 

Infusion related reactions (also see section 4.4 Special warnings and precautions for use) may also include cardiac events such as cardiac arrhythmias (atrial fibrillation, ventricular extrasystoles, tachyarrhythmia), myocardial ischemia, and heart failure in patients with Fabry disease involving the heart structures.  Infusion-related symptoms may include dizziness and hyperhidrosis. The most frequent were mild infusion-related reactions that mainly included rigors, pyrexia, flushing, headache, nausea, and dyspnoea.

 

Adverse drug reactions reported in the paediatric population (children and adolescents) were, in general, similar to those reported in adults.  However, infusion related reactions (pyrexia, dyspnoea, chest pain) and pain exacerbation occurred more frequently. 

 


In section 5.1 (Pharmacodynamic properties), has been updated to specify paediatric sub-populations.

The safety and efficacy of Replagal was assessed in two randomised, double blind, placebo controlled studies and open label extension studies, in a total of forty patients with a diagnosis of Fabry Disease based on clinical and biochemical evidence.  Patients received the recommended dosage of 0.2 mg/kg of Replagal.  Twenty-five patients completed the first study and entered an extension study.  After 6 months of therapy there was a significant reduction in pain in the Replagal treated patients compared with placebo (p=0.021), as measured by the Brief Pain Inventory (a validated pain measurement scale).  This was associated with a significant reduction in chronic neuropathic pain medication use and number of days on pain medication.  In subsequent studies, in male paediatric patients above the age of 7, a reduction in pain was observed after 9 and 12 months of Replagal therapy compared to pre-treatment baseline. This pain reduction persisted through 4 years of Replagal therapy in 9 patients (in patients 7 – 18 years of age). 

 

Twelve to 18 months of treatment with Replagal resulted in improvement in quality of life (QoL), as measured by validated instruments. For patients between 0 and 7 years of age, limited data indicate no specific safety issues.

 

In male paediatric Fabry patients > 7 years of age, hyperfiltration can be the earliest manifestation of renal involvement in the disease.  Reduction in their hypernormal eGFRs was observed within 6 months of initiating Replagal therapy. After one year of treatment with agalsidase alfa 0.2mg/kg every other week, the abnormally high eGFR decreased from 143.4 ± 6.8 to 121.3 ± 5.6 mL/min/1.73 m2 in this subgroup and these eGFRs stabilized in the normal range during 4 years of Replagal 0.2mg/kg therapy, as did the eGFRs of the non-hyperfiltrators.

 

In male paediatric patients > 7 years of age, heart rate variability was abnormal at baseline and improved after 6 months of Replagal therapy in 15 boys and the improvement was sustained through 4.0 years of Replagal 0.2mg/kg therapy in an open-label long-term extension study in 9 boys.  Individual left ventricular mass indexed to height2.7 was within normal range for children (<39 g/m2.7 in boys) at baseline.  A relative reduction in mean LVM of 11% was observed during the 4.5 years of treatment. In  5/6 children < 7 years old, individual left ventricular mass indexed to height 2.7 was borderline elevated or elevated (>95%) for (<39 g/m2.7 in boys) at baseline.  LVMI values for all 5 children fell within normal range after starting therapy.

 

In male paediatric Fabry patients plasma Gb3 decreased 40-50% after 6 months of Replagal therapy 0.2mg/kg and this reduction persisted after a total 4 years of treatment in 11 patients.


In section 10 (Date of revision of the text), has been updated to 12/2009.

Updated on 01/06/2009 and displayed until 02/02/2010
Reasons for adding or updating:
  • Change to section 7 - Marketing authorisation holder
Date of revision of text on the SPC:   30-Oct-2008
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

Change in contact details of MAH
Updated on 26/08/2008 and displayed until 01/06/2009
Reasons for adding or updating:
  • New SPC for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Agalsidase alfa

Versions

 
28/03/2012 to Current
02/02/2010 to 28/03/2012
01/06/2009 to 02/02/2010
26/08/2008 to 01/06/2009
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo